AI-generated from publicly available materials.Asleep, an innovative AI startup specializing in sleep disorder diagnostics, is shifting its focus from wellness applications to the prescription market, establishing partnerships with major pharmaceutical companies.
The company recently signed a distribution agreement with Handok for its digital medical device, Chronotrack, which automates the recording of sleep patterns. This follows a previous partnership with Chong Kun Dang for Apnotrack, a tool designed to diagnose sleep apnea. Chronotrack offers a modern alternative to traditional sleep diaries, tracking breathing and movement over two weeks and generating clinical reports that aid physicians in assessing sleep health.
Asleep's growth is backed by substantial real-world data, revealing concerning trends in sleep patterns among South Koreans, such as a high prevalence of "night owls." Research indicates that maintaining regular sleep schedules is a critical health indicator, with irregular patterns linked to increased mortality risk. This data positions Asleep's offerings as valuable tools for pharmaceutical companies aiming to enhance disease management in sleep-related conditions.
Asleep's strategic collaborations aim to create a comprehensive sleep care ecosystem, integrating diagnostic tools with existing treatments. This approach not only enhances the clinical credibility of its products but also leverages pharmaceutical sales networks to penetrate the early prescription market. Asleep's model exemplifies the merging of digital health and traditional medicine, potentially transforming insomnia treatment paradigms.